ArQule wanted a partner. Merck wanted control. Solution A buyout deal
It’s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.’s $2.7 billion deal for ArQule. ArQule started looking for a co-development, profit-sharing partnership for its BTK inhibitor ARQ 531 around 2018. But after Merck decided it wanted “greater control,†the industrious New Jersey pharma instead negotiated an acquisition deal in 20 days. Initially, it wasn’t just Merck interested in ARQ 531. At least six companies—and we have a few guesses who—were intrigued enough to dig into due diligence at some point between 2018 and 2019, according to a securities filing.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
